Positron Emission Tomography PET Radiotracer Market 2024: Key Trends, Innovations, and Growth Prospects

The positron emission tomography (pet) radiotracer global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Positron Emission Tomography (PET) Radiotracer Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size -
The positron emission tomography (PET) radiotracer market size has grown strongly in recent years. It will grow from $2.15 billion in 2023 to $2.35 billion in 2024 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to the increasing prevalence of infectious diseases, increasing awareness and accessibility, the emergence of novel radiotracers, the rising prevalence of cancer, and the increasing focus on preventive medicine.

The positron emission tomography (PET) radiotracer market size is expected to see strong growth in the next few years. It will grow to $3.33 billion in 2028 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to the expansion of applications, regulatory approvals, growth in emerging markets, growing geriatric population, and growing adoption of PET radio scanners. Major trends in the forecast period include the development of micro-pet technology, integration with wearable technology, expansion of theranostics, nano-radiotracers, and blockchain for data security.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/positron-emission-tomography-pet-radiotracer-global-market-report

Scope Of Positron Emission Tomography (PET) Radiotracer Market
The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Positron Emission Tomography (PET) Radiotracer Market Overview

Market Drivers -
The increasing prevalence of infectious diseases is expected to propel the growth of the positron emission tomography (PET) radiotracer market going forward. Infectious diseases refer to illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites. The rising prevalence of infectious diseases is due to climate change, urbanization, globalization, antibiotic resistance, and changes in human behavior, which all facilitate the spread of pathogens. Positron emission tomography (PET) radiotracers help infectious diseases by visualizing metabolic activity and inflammation, enabling detection of infection, assessment of treatment response, and differentiation between infectious and non-infectious conditions for better patient outcomes. For instance, in February 2024, according to a report published by the UK Health Security Agency, a UK-based government agency, tuberculosis (TB) cases in England increased by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Therefore, the increasing prevalence of infectious diseases is driving the growth of the positron emission tomography (PET) radiotracer market.

Market Trends -
Major companies operating in the positron emission tomography (PET) radiotracer market are focusing on developing advanced diagnostic solutions, such as positron emission tomography imaging agents to enhance cancer detection and improve patient outcomes. A positron emission tomography (PET) imaging agent refers to a radioactive substance used to visualize and measure biological processes in the body during PET scans. For instance, in March 2023, IsoLogic Innovative Radiopharmaceuticals, a Canada-based radiopharmaceutical company, launched Illuccix, also known as the Ga-68 Gozetotide Preparation Kit (PSMA-11), in Canada as a prostate cancer imaging agent designed to detect metastatic prostate cancer. This tool is valuable for physicians in identifying metastatic disease and aiding in patient management decisions. It is indicated for use in patients suspected of having metastasis who are candidates for initial definitive therapy, as well as in those with suspected recurrence indicated by elevated serum prostate-specific antigen (PSA) levels.

The positron emission tomography (PET) radiotracer market covered in this report is segmented -

1) By Radiotracer Type: F-18 (Fluorodeoxyglucose 18), Ga-68 (Fibroblast Activation Protein Inhibitor), Other Radiotracer Types
2) By Application: Cancer, Heart Disease, Gastrointestinal, Endocrine, Neurological Disorders, Other Applications
3) By End-User: Hospitals, Diagnostic Centers, Other End-Users

Get an inside scoop of the positron emission tomography (pet) radiotracer market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=19152&type=smp

Regional Insights -
North America was the largest region in the positron emission tomography (PET) radiotracer market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the positron emission tomography (PET) radiotracer marker report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies -
Major companies operating in the positron emission tomography (PET) radiotracer marker are Cardinal Health Inc., AstraZeneca PLC, Eli Lilly and Company, Siemens Healthineers AG, GE Healthcare Technologies Inc., Philips Healthcare, Bracco Imaging S.p.A., Neusoft Medical Systems Co Ltd., Lantheus Holdings Inc., Jubilant Pharma Limited, SOFIE Biosciences (SOFIE), Yantai Dongcheng Pharmaceutical Group Co. Ltd., Nordion Inc., RefleXion Medical Inc., Isologic Innovative Radiopharmaceuticals, ABX Advanced Biochemical Compounds GmbH, IBA Radiopharma Solutions S.A., IXICO PLC, ImaginAb Inc., Radiomedix Inc.

Table of Contents
1. Executive Summary
2. Positron Emission Tomography (PET) Radiotracer Market Report Structure
3. Positron Emission Tomography (PET) Radiotracer Market Trends And Strategies
4. Positron Emission Tomography (PET) Radiotracer Market - Macro Economic Scenario
5. Positron Emission Tomography (PET) Radiotracer Market Size And Growth
…..
27. Positron Emission Tomography (PET) Radiotracer Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

This release was published on openPR.